HUP9901794A3 - Administration regimen of h+,k+-atpase inhibitors - Google Patents

Administration regimen of h+,k+-atpase inhibitors

Info

Publication number
HUP9901794A3
HUP9901794A3 HU9901794A HUP9901794A HUP9901794A3 HU P9901794 A3 HUP9901794 A3 HU P9901794A3 HU 9901794 A HU9901794 A HU 9901794A HU P9901794 A HUP9901794 A HU P9901794A HU P9901794 A3 HUP9901794 A3 HU P9901794A3
Authority
HU
Hungary
Prior art keywords
administration regimen
atpase inhibitors
atpase
inhibitors
regimen
Prior art date
Application number
HU9901794A
Other languages
English (en)
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of HUP9901794A2 publication Critical patent/HUP9901794A2/hu
Publication of HUP9901794A3 publication Critical patent/HUP9901794A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
HU9901794A 1996-06-20 1997-06-18 Administration regimen of h+,k+-atpase inhibitors HUP9901794A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9602442A SE9602442D0 (sv) 1996-06-20 1996-06-20 Administration of pharmaceuticals

Publications (2)

Publication Number Publication Date
HUP9901794A2 HUP9901794A2 (hu) 2000-04-28
HUP9901794A3 true HUP9901794A3 (en) 2002-11-28

Family

ID=20403092

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901794A HUP9901794A3 (en) 1996-06-20 1997-06-18 Administration regimen of h+,k+-atpase inhibitors

Country Status (28)

Country Link
US (4) US20010008900A1 (hu)
EP (1) EP0921787B1 (hu)
JP (1) JP2000512993A (hu)
CN (1) CN1178648C (hu)
AT (1) ATE252885T1 (hu)
AU (1) AU726859B2 (hu)
BR (1) BR9709838A (hu)
CA (1) CA2257405A1 (hu)
CZ (1) CZ298213B6 (hu)
DE (1) DE69725860T2 (hu)
DK (1) DK0921787T3 (hu)
EE (1) EE04606B1 (hu)
ES (1) ES2208921T3 (hu)
HK (1) HK1018590A1 (hu)
HU (1) HUP9901794A3 (hu)
IL (2) IL127542A0 (hu)
IS (1) IS2216B (hu)
NO (1) NO323295B1 (hu)
NZ (1) NZ332990A (hu)
PL (1) PL189716B1 (hu)
PT (1) PT921787E (hu)
RS (1) RS49590B (hu)
RU (1) RU2203662C2 (hu)
SE (1) SE9602442D0 (hu)
SK (1) SK284204B6 (hu)
TR (1) TR199802647T2 (hu)
UA (1) UA64715C2 (hu)
WO (1) WO1997048380A1 (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
WO1999055157A1 (en) * 1998-04-30 1999-11-04 Sepracor Inc. R-rabeprazole compositions and methods
AU3967399A (en) * 1998-04-30 1999-11-16 Sepracor, Inc. S-rabeprazole compositions and methods
BR9912937A (pt) 1998-08-10 2001-05-08 Partnership Of Michael E Garst Pró-drogas de inibidores de bomba de prótons
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
ATE321538T1 (de) 1998-08-12 2006-04-15 Altana Pharma Ag Orale darreichungsform für pyridin-2- ylmethylsulfinyl-1h-benzimidazole
US20050048077A1 (en) * 2002-02-21 2005-03-03 George Sachs Compositions, test kits and methods for detecting helicobacter pylori
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP5563735B2 (ja) 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5330982A (en) * 1986-12-17 1994-07-19 Glaxo Group Limited Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith
EP0695123A4 (en) * 1993-04-27 1996-09-11 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATING GASTRICAL FAULTS USING OPTICALLY PURE PANTOPRAZOLS
PT1078628E (pt) * 1994-07-08 2009-01-27 Astrazeneca Ab Forma de dosagem em comprimidos com unidades múltiplas
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole

Also Published As

Publication number Publication date
HK1018590A1 (en) 1999-12-30
SK165598A3 (en) 1999-08-06
CN1178648C (zh) 2004-12-08
US20090036494A1 (en) 2009-02-05
US20010008900A1 (en) 2001-07-19
PT921787E (pt) 2004-03-31
AU726859B2 (en) 2000-11-23
EE04606B1 (et) 2006-04-17
NO985964L (no) 1999-02-22
BR9709838A (pt) 1999-08-10
US20050113418A1 (en) 2005-05-26
IS2216B (is) 2007-03-15
YU56698A (sh) 2004-12-31
SE9602442D0 (sv) 1996-06-20
ATE252885T1 (de) 2003-11-15
CZ298213B6 (cs) 2007-07-25
CA2257405A1 (en) 1997-12-24
RU2203662C2 (ru) 2003-05-10
DE69725860T2 (de) 2004-09-09
CZ420398A3 (cs) 2000-02-16
IL127542A0 (en) 1999-10-28
TR199802647T2 (xx) 1999-03-22
DE69725860D1 (de) 2003-12-04
RS49590B (sr) 2007-06-04
US20070276007A1 (en) 2007-11-29
DK0921787T3 (da) 2004-02-23
ES2208921T3 (es) 2004-06-16
SK284204B6 (sk) 2004-10-05
AU3469097A (en) 1998-01-07
PL189716B1 (pl) 2005-09-30
PL330910A1 (en) 1999-06-07
IS4923A (is) 1998-12-15
NO323295B1 (no) 2007-03-05
CN1222074A (zh) 1999-07-07
EP0921787B1 (en) 2003-10-29
NZ332990A (en) 2000-07-28
WO1997048380A1 (en) 1997-12-24
UA64715C2 (en) 2004-03-15
EP0921787A1 (en) 1999-06-16
IL127542A (en) 2006-08-01
HUP9901794A2 (hu) 2000-04-28
EE9800435A (et) 1999-06-15
JP2000512993A (ja) 2000-10-03
NO985964D0 (no) 1998-12-18

Similar Documents

Publication Publication Date Title
HUP9901794A3 (en) Administration regimen of h+,k+-atpase inhibitors
GB2331015B (en) Therapeutic methods and compositions involving isoflavones
PL328399A1 (en) Drug administration aid
EP0875074A4 (en) SEMICONDUCTOR DEVICES AND RELATED METHODS
SI0934320T1 (en) Naphthyridine derivatives
HUP9902455A3 (en) 6-phenylpyridyl-2-amine derivatives, pharmaceutical compositions containing them
AU4677399A (en) Inhibitors of H+K+-ATPase
PL332432A1 (en) Oxadiazoles, method of obtaining them as well as their application as therapeutic agents
GB9816510D0 (en) Avermectin formulation
IL119994A0 (en) 2-oxo- and 2-thio-1,2-dihydroquinolinyl-oxazolidinones their preparation and pharmaceutical compositions containing them
AU2879300A (en) Methods for anti-tumor therapy
PL314732A1 (en) S(+)-ethodolac preparations for oral administration
PL322526A1 (en) Azathiopyrin compositions for intracolic administration
EP0656791A4 (en) THERAPEUTIC COMPOSITIONS AND METHODS BASED ON 2,7,9-TRICARBOXY-PYRROLOQUINOLEINE (PQQ).
HK1022432A1 (en) Administration of histamine for therapeutic purposes.
IL128806A0 (en) Compositions for immune therapy
GB9601186D0 (en) Administration of Drugs
AU4415797A (en) New pde iv inhibitors: "bis-compounds"
HK1042901A1 (en) Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
AU4636396A (en) Antiglucocorticoid medicament
HUP0102772A3 (en) Novel compounds derived from alpha-d-xylose, preparation method and therapeutic use
SI0921787T1 (en) ADMINISTRATION REGIMEN OF H+,K+-ATPase INHIBITORS
AU4003497A (en) Therapeutic methods and compositions involving isoflavones
AU3423397A (en) Therapeutic methods and compositions for use therein
IL125523A0 (en) Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)